An observational study in AI (Artificial Intelligence), Pulmonary Nodule, Solitary and Pulmonary Nodule, Multiple, sponsored by Nottingham University Hospitals NHS Trust. Recruiting at 10 sites in United Kingdom. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Nottingham University Hospitals NHS Trust · Observational
This study is a multi-centre prospective observational cohort study recruiting patients with 5-30mm solid and part-solid pulmonary nodules that have been detected on CT chest scans performed as part of routine practice. The aim is to determine whether physician decision making with the AI-based LCP tool, generates clinical and health-economic benefits over the current standard of care of these patients.
93 studies on the registry are indexed under Solitary Pulmonary Nodule; 20 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 401 across 45 observational studies indexed under Solitary Pulmonary Nodule.
Browse Solitary Pulmonary Nodule studies →Nottingham University Hospitals NHS Trust is the lead sponsor of 107 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The CT scans of patients for whom a pulmonary nodule has been identified will be reviewed for study eligibility by a member of the local site's clinical team for the patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible for the study if all of the following apply:
Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component >=80%) pulmonary nodule that:
Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided):
Exclusion Criteria:
Patients will be excluded from the study if any of the following apply:
Have one or more additional nodules where any of the following applies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Determine the potential effect of the LCP on discharge
Measured difference between standard care, LCP and LCP-guided care for: * Percentage of cancer patients discharged (straight after assessment of the baseline scan) * Percentage of benign-nodule patients discharged (straight after assessment of the baseline scan)
Time frame: up to 1 year.
Determine the potential effect of the LCP on overall clinical management, as well as scan and procedure utilization.
Percentage of cancer patients for whom there would have been a change in clinical management by LCP and LCP-guided care compared with the actual (standard) care (correctly by more aggressive management and incorrectly for less aggressive management). Percentage of benign-nodule patients for whom there would have been a change in clinical management by LCP and LCP-guided care compared with the actual (standard) care (incorrectly by more aggressive management and correctly for less aggressive management). Measured difference between standard care, LCP and LCP-guided care for: * Percentage of CT scans and PET/CT scans performed on benign-nodule patients * Percentage of non-surgical biopsies performed on benign-nodule patients * Percentage of surgical excisions on benign-nodule patients
Time frame: up to 1 year.
Determine the potential effect of the hypothetical LCP-informed care versus standard care on patient outcomes.
Measured difference between standard care, LCP and LCP-guided care for: * Percentage of thoracic, respiratory or vascular events related to biopsies or surgical excisions for lung nodules or suspected lung cancer occurring within 30 days of the procedure on benign-nodule patients * Percentage of lung cancers stratified by stage * Time in days between nodule detection and lung cancer diagnosis
Time frame: up to 1 year.
Determine the potential health-economic effect of the hypothetical LCP-informed care versus standard care
Measured difference between standard care, LCP and LCP-guided care for: * The composite standardized GBP costs of all healthcare-related activity for lung nodules or suspected lung cancer * Health-related utilities (life years and QALYs)
Time frame: up to 1 year.
Determine the potential effect of the LCP on possible adherence to clinical guidelines.
Measured difference between standard care and LCP-guided care for : Number and percentage of patients for whom a validated risk model (Brock or LCP) is used to guide the next clinical management step (i.e., counting the instances where Brock is not used, or where LCP is not possible to compute or it is ignored).
Time frame: up to 1 year.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nottingham University Hospitals NHS Trust →